Luc Debruyne graduated from the Katholieke Universiteit van Leuven (KU Leuven) and attended a sustainability leadership program at the Institute for Sustainability Leadership at the University of Cambridge. He is an established business leader with more than 30 years of experience in the life sciences industry, 27 of which he spent at GlaxoSmithKline (GSK).
Debruyne joined GSK in 1991 as a commercial strategy director in R&D and has served in multiple capacities in many countries since then. From 2013 to the end of 2018, he ran GSK’s Global Vaccines Business and was a member of the GSK corporate executive team. Under his watch, GSK became the #1 vaccine company worldwide, leading the launch of several successful vaccines including Shingrix, which protects against shingles.
Debruyne is highly regarded as an active contributor and advisor in the global health arena, cooperating in multilateral fora and building strong relationships with governments, NGOs, academic institutions and more. He has broad functional leadership experience in research and development and commercial, manufacturing and quality operations.
Debruyne continues to be a strong promotor of sustainable business practices. He was recently appointed as a member of the board of Fund+, an investment firm focused on innovative European life sciences companies. Debruyne is, among other roles, strategy advisor to CEPI (Coalition Epidemic Preparedness Innovations) and a member of the I.A.B. (Institutional Advisory Board) of VIB (Flanders Institute for Biotechnology), Life Science Advisory Board member for Greenlight Biosciences and research fellow within the Economics & Business Faculty of KU Leuven. He is a non-executive director at university hospital UZ Leuven.